A Phase III, Multicentre, Double-Blind, Double-Dummy, Randomised, Flexible-Dose, Comparative Study of MCI-196 Versus Simvastatin for the Treatment of Dyslipidaemia in Subjects With Chronic Kidney Disease on Dialysis (Incorporating a Placebo-Controlled Withdrawal Phase).

Trial Profile

A Phase III, Multicentre, Double-Blind, Double-Dummy, Randomised, Flexible-Dose, Comparative Study of MCI-196 Versus Simvastatin for the Treatment of Dyslipidaemia in Subjects With Chronic Kidney Disease on Dialysis (Incorporating a Placebo-Controlled Withdrawal Phase).

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Nov 2014

At a glance

  • Drugs Colestilan (Primary) ; Simvastatin
  • Indications Dyslipidaemias
  • Focus Therapeutic Use
  • Sponsors Mitsubishi Tanabe Pharma Corporation
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 15 Mar 2012 Actual end date changed from 1 Mar 2010 to 22 Jun 2011 as reported by EudraCT.
    • 13 Apr 2010 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top